Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.
Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.
Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.
An experimental drug from AtheroGenics and its partner AstraZeneca failed a late-stage clinical trial and is not considered an effective treatment in reducing heart disease, the companies said.
All this reading of the tea leaves of Fed meeting minutes makes my brain hurt! I mean talk about white noise. Here's a question: Will the action pick up after Labor Day?
Merck and Schering-Plough announced a study on Sunday showing that their combination drug Vytorin is better at lowering cholesterol than competing drug Crestor from AstraZeneca.
A new study shows that Vytorin, a cholesterol drug from Merck and Schering-Plough that combines Zocor and Zetia, significantly reduces cholesterol when compared to Zocor alone, the company said.
Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.
Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.
Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.
An experimental drug from AtheroGenics and its partner AstraZeneca failed a late-stage clinical trial and is not considered an effective treatment in reducing heart disease, the companies said.
All this reading of the tea leaves of Fed meeting minutes makes my brain hurt! I mean talk about white noise. Here's a question: Will the action pick up after Labor Day?
Merck and Schering-Plough announced a study on Sunday showing that their combination drug Vytorin is better at lowering cholesterol than competing drug Crestor from AstraZeneca.
A new study shows that Vytorin, a cholesterol drug from Merck and Schering-Plough that combines Zocor and Zetia, significantly reduces cholesterol when compared to Zocor alone, the company said.
Vytorin, a relatively new cholesterol-blocking drug from Merck and Schering-Plough, has outpaced sales of a blockbuster rival, according to a report Monday from Friedman, Billings, Ramsey & Co.
Sales for Vytorin, a cholesterol-treating combination produced by Merck and Schering-Plough, have grown since its market debut last summer, but the drug's real test lies ahead, analysts say.
In an industry characterized by change, Samuel Isaly has been a rare constant. Since becoming a drug analyst at age 23, after graduating from the London School of Economics, the manager of the $2 ...
In the future, successful drug companies will have to come up with innovative cures for complex, hard-to-treat conditions like cancer -- without letting their research-and-development spending get out of hand.
While Wall Street wants to break conglomerates into smithereens, the pharmaceuticals business is heading in the opposite direction. If approved, Pfizer's $60 billion purchase of Pharmacia will crea...
The page you requested cannot be found. The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.
Please try the following:
• If you typed the page address in the Address bar, make sure that it is spelled correctly.
• Open the edition.cnn.com home page and look for links to the information you want.
• Use the navigation bar above to find the link you are looking for.
• Click the Back button to try another link.
• Enter a term in the search form below to look for information on CNN sites or the Internet.
Video
